Senolytic Composition Targeting COX and ACSL Enzymes

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current senolytic compounds often have severe side effects and are not universally effective across all cell types, highlighting a need for improved senolytics with broader applications and fewer side effects.

Innovation Solution

A composition comprising inhibitors of cyclooxygenase-1 (COX-1), cyclooxygenase-2 (COX-2), and lipoxygenase enzymes, along with inhibitors of arachidonate-CoA ligase activity, specifically targeting senescent cells by altering their lipid metabolism to induce selective elimination.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If current senolytic compounds are used to eliminate senescent cells, then senescent cells are removed, but severe side effects occur and effectiveness is limited to specific cell types

Engineering Contradiction:

Improveselectivity toward senescent cellsVSAvoidside effects

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent applies local quality by targeting a specific metabolic pathway (arachidonic acid metabolism via COX and lipoxygenase enzymes) that is locally altered in senescent cells. Senescent cells exhibit elevated expression of these enzymes and increased arachidonic acid levels, creating a localized metabolic vulnerability that can be selectively exploited without affecting other cell types, thereby reducing systemic side effects while maintaining high selectivity.

Inventive Principle:

Principle #3Local quality

Solution Approach 2:

The patent utilizes parameter changes by focusing on the altered metabolic state of senescent cells, specifically the increased arachidonic acid levels and upregulated COX/lipoxygenase activity. By administering compounds that inhibit these enzymes, the patent changes the metabolic parameters of senescent cells, leading to toxic accumulation of arachidonic acid derivatives that selectively kill senescent cells while sparing healthy cells with normal metabolic profiles.

Inventive Principle:

Principle #35Parameter changes

2Adaptability or versatility

If current senolytic compounds are used, then senescent cells are eliminated, but the compounds are not universally effective across all cell types

Engineering Contradiction:

Improvebroad applicability across cell typesVSAvoidselectivity toward senescent cells

Core Design Contradiction:

Adaptability or versatilityVSReliability

Solution Approach 1:

The patent achieves universality by targeting a fundamental metabolic pathway (arachidonic acid metabolism) that is dysregulated in senescent cells across diverse tissue types and cell lineages. The COX and lipoxygenase enzymes are ubiquitously expressed in mammalian cells, and their altered activity in senescence represents a universal hallmark of the senescent state, enabling broad applicability of the senolytic approach across different cell types while maintaining selectivity through the specific metabolic vulnerability.

Inventive Principle:

Principle #6Universality (Multi-functionality)

3Reliability

If arachidonic acid metabolism is inhibited in senescent cells, then selective elimination occurs, but intracellular arachidonic acid accumulation must be prevented

Engineering Contradiction:

Improveselective elimination of senescent cellsVSAvoidintracellular arachidonic acid accumulation

Core Design Contradiction:

ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The patent applies blessing in disguise by converting the harmful effect of arachidonic acid accumulation into a beneficial therapeutic mechanism. Instead of preventing arachidonic acid accumulation (which would require complex multi-enzyme inhibition), the patent exploits the fact that senescent cells already have elevated arachidonic acid levels and upregulated metabolic enzymes. By partially inhibiting COX and lipoxygenase, the patent creates a controlled accumulation that overwhelms the already stressed senescent cell metabolism, turning potential toxicity into selective cell death while healthy cells compensate for the inhibition.

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The solution effectively eliminates senescent cells by preventing cell death from intracellular arachidonic acid accumulation, demonstrating a selective and efficient approach with reduced side effects and broader applicability compared to existing senolytics.

Implementation Method 1

A composition comprising inhibitors of cyclooxygenase-1 (COX-1), cyclooxygenase-2 (COX-2), and lipoxygenase enzymes

Methodology Applied

Scientific EffectEnzyme inhibition: Enzyme

Implementation Method 2

inhibitors of arachidonate-CoA ligase activity, specifically targeting senescent cells by altering their lipid metabolism

Methodology Applied

Scientific EffectEnzyme inhibition: Enzyme

Data Source

PatentUS20210379087A1Compositions for the elimination of senescent cells

Publication Date: 2021.12.09 MEDIZINISCHE UNIVERSITAET WIEN

AI summary

The invention relates to a composition comprising one or more inhibitors capable of inhibiting at least two of cyclooxygenase-1 (COX-1), cyclooxygenase-2 (COX-2) and lipoxygenase or a composition comprising one or more inhibitors capable of inhibiting an enzyme with arachidonate-Co A ligase activity, specifically long-chain-fatty-acid-Co A ligase (ACSL) 1, ACSL3, ACSL4, ACSL5, ACSL6, SLC27A2 or ACSBG2, or a combination thereof for use in selectively eliminating senescent cells. The invention further relates to an in vitro method of identifying senescent cells in a subject and to a method of identifying candidate compounds for the selective elimination of senescent cells.